Mereo BioPharma to Present at Two Upcoming Investor Conferences

NEXT STORY
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
PREV STORY
The Worldwide Biosimilars Industry is Expected to Reach $44.7 Billion by 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

author_avatar
NASDAQ Market News

Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections

Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead ...

author_avatar
NASDAQ Market News

Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis Patients

NEW YORK and MELBOURNE, Australia, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) ...

author_avatar
NASDAQ Market News